• Quick Order
  • Careers
  • Support
Checkpoint inhibitor therapeutic antibody blocking PD-1 protein on T cell and preventing it to bind to PD-1L on cancer cell

Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

San Diego Convention Center, San Diego, California

November 01, 2023 - November 05, 2023

The SITC Annual Meeting brought together a global community of scientists focused on cancer immunotherapy and tumor immunology. Check out our poster presentations from the event and explore our immune checkpoint reporter cells, CAR-T luciferase reporter cells, THP-1 reporter cells, 2-D and 3-D patient-derived cancer models, human primary cells, and cancer panels to see how we can support your work!

Did you miss us at booth #731 and want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.

Contact us

Fluorescent blue and green spheres of leukemic cells.

Join our immunotherapy innovation challenge

Join the challenge

Check out our poster presentations

Optimizing ex vivo CAR-T cell-mediated cytotoxicity assay through multimodality imaging
Presenter: John Foulke, MS, Lead Biologist, ATCC
Date: Friday, November 3, 2023
Time: 9:00 AM – 7:00 PM
Abstract number: 81

Get the poster

GAS-Luc2 reporter cell lines for immune checkpoint drug screening in solid tumors
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: Saturday, November 4, 2023
Time: 9:00 AM – 7:00 PM
Abstract number: 496

Get the poster

Meet the presenters

John Foulke, headshot

John Foulke, MS

Lead Biologist, ATCC

John Foulke is a Lead Biologist in the Immuno-Oncology group in the R&D department at ATCC. John joined the ATCC cell biology R&D group in 2008, and he has led many projects centered on the development of novel cell lines and cell-based reporter systems to support cancer research community. His work is mainly focused on developing innovative cell models for research and drug discovery in the immuno-oncology field.

Hyeyoun Chang, headshot

Hyeyoun Chang, PhD

Scientist, ATCC

Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School. 

Contact us today!

Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.

We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form has been successfully submitted